Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 76, Issue 1, Pages 79-87
Publisher
BMJ
Online
2016-08-24
DOI
10.1136/annrheumdis-2016-209709
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis
- (2016) A.B. Kimball et al. BRITISH JOURNAL OF DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brief Report: Enrichment of Activated Group 3 Innate Lymphoid Cells in Psoriatic Arthritis Synovial Fluid
- (2015) Emmerik F. A. Leijten et al. Arthritis & Rheumatology
- Current Concepts in Psoriatic Arthritis: Pathogenesis and Management
- (2014) K Vlam et al. ACTA DERMATO-VENEREOLOGICA
- Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
- (2014) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunomodulation in psoriatic arthritis: Focus on cellular and molecular pathways
- (2012) Maria Sole Chimenti et al. AUTOIMMUNITY REVIEWS
- Role of IL-17 in Psoriasis and Psoriatic Arthritis
- (2012) Siba P. Raychaudhuri CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
- (2012) Craig Leonardi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis
- (2011) Troy Noordenbos et al. ARTHRITIS AND RHEUMATISM
- Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
- (2011) A. M. Lin et al. JOURNAL OF IMMUNOLOGY
- Minimally Important Difference of Health Assessment Questionnaire in Psoriatic Arthritis: Relating Thresholds of Improvement in Functional Ability to Patient-rated Importance and Satisfaction
- (2011) P. J. MEASE et al. JOURNAL OF RHEUMATOLOGY
- Psoriatic arthritis
- (2009) Dafna D. Gladman Dermatologic Therapy
- Circulating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
- (2009) Shinji Kagami et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
- (2008) G Wells et al. ANNALS OF THE RHEUMATIC DISEASES
- Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides
- (2008) Camilla Jandus et al. ARTHRITIS AND RHEUMATISM
- Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis
- (2008) Paul J. Healy et al. ARTHRITIS AND RHEUMATISM
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More